CurrentEndo
Get Weekly

Topic

Lipids & metabolic liver disease

Lipid disorders and metabolic dysfunction-associated steatotic (fatty) liver disease, as published in the endocrine journals

CurrentEndo holds 460 Briefs in Lipids & metabolic liver disease, most often cohort studies and cross-sectional studies; the journals with the most are Cardiovasc Diabetol, Diabetes Obes Metab and J Clin Endocrinol Metab.

460 Briefs placed here193 more Briefs indexed under this topic as a secondary topic

Briefs in Lipids & metabolic liver disease

Newest publication first

  1. Diabetes Res Clin Pract

    Cross-national associations of atherogenic index of plasma and frailty with cardiometabolic multimorbidity: evidence from China, England, and Europe

    Cohort study

  2. Diabetologia

    Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease

    Cohort study

  3. Cardiovasc Diabetol

    Cumulative estimated glucose disposal rate and longitudinal eGDR patterns in relation to incident cardiovascular disease among middle-aged and older adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

    Cohort study

  4. Cardiovasc Diabetol

    Antecedent, landmark, and two-visit cumulative triglyceride-glucose index and non-traditional lipid measures in relation to incident cardiovascular disease in adults with cardiovascular-kidney-metabolic syndrome (CKM) stages 0–3: a nationwide prospective cohort study

    Cohort study

  5. Diabetes Obes Metab

    Association of Phenotypic Age Acceleration With Pancreatic Fat Percentage in a UK Biobank Imaging Population

    Cross-sectional study

  6. Diabetes Obes Metab

    Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD : A Systematic Review and Meta‐Analysis

    Meta-analysis

  7. Diabetes Obes Metab

    Sex‐Stratified Associations of DXA ‐Derived Adiposity, Regional Fat Distribution and Muscle Power With Incident Hospitalised Cardiovascular Disease in Older Adults: A Prospective Cohort Study

    Cohort study

  8. Diabetes Obes Metab

    Short‐Term Changes in General and Central Adiposity and Subsequent Cardiometabolic Risk in Japanese Adults Undergoing Routine Health Screening

    Cohort study

  9. Diabetes Res Clin Pract

    Prevalence of fatty liver and diabetes mellitus in patients with fatty pancreas disorder (FPD): A meta-analysis and systematic review

    Meta-analysis

  10. Diabetes Obes Metab

    Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD : A 16‐Week, Double‐Masked, Randomized Controlled Trial

    Randomized controlled trial

  11. Diabetes Res Clin Pract

    Temporal evolution of tissue-specific insulin resistance and transitions in MASLD status: a retrospective longitudinal cohort study

    Cohort study

  12. Cardiovasc Diabetol

    Composite C-reactive protein-triglyceride-glucose adiposity indices and incident cardiovascular-liver-metabolic multimorbidity: a prospective cohort study

    Cohort study

  13. Diabetes Res Clin Pract

    Correlative association between FIB-4 index and graded coronary artery disease severity among MASLD patients: A hypertension-stratified analysis

    Cross-sectional study

  14. Cardiovasc Diabetol

    The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study

    Cohort study

  15. Diabetes Metab

    Lower glucagon response and attenuated hepatic glucagon signaling in MASLD

    Cross-sectional study

  16. Diabetes Obes Metab

    Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials

    Meta-analysis

  17. Thyroid

    Liver, Portal, and Systemic Thyroid Hormone Concentrations in End-Stage MASH Reveal Distinct Roles for T3/rT3 Ratio and T4

    Cross-sectional study

  18. BMJ Open Diabetes Res Care

    Association between liver fibrosis severity and impaired myocardial glucose metabolism in subjects with different degrees of glucose tolerance

    Cross-sectional study

  19. Diabetes Obes Metab

    Closer Association of Liver Stiffness Than Liver Fat Content With Imaging‐Derived Neurovascular Coupling in a Metabolic Dysfunction‐Associated Steatotic Liver Disease Cohort

    Cross-sectional study

  20. Diabetes Obes Metab

    Changes in Muscle Mass and the Risk of Liver‐Related Events: A Prospective Cohort Study

    Cohort study

  21. Diabetes Res Clin Pract

    Evidence from two large prospective cohorts: variations in remnant cholesterol inflammation index and the risk of cardiometabolic multimorbidity in middle-aged and elderly populations

    Cohort study

  22. Int J Obes (Lond)

    Adopting the lancet commission definition of clinical obesity in metabolic dysfunction-associated steatotic liver disease (MASLD)

    Cohort study

  23. Cardiovasc Diabetol

    Lipoprotein(a), insulin resistance, and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease

    Cohort study

  24. Cardiovasc Diabetol

    Sex- and menopause-specific inverse associations between metabolic dysfunction–associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank

    Cross-sectional study

  25. Cardiovasc Diabetol

    Frailty may confound the association between MASLD and cardiovascular mortality in people with cardiometabolic risk factors

    Cohort study

  26. Diabetes Res Clin Pract

    Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with CKM stages 0–2: Mediating roles of inflammation and insulin resistance

    Cohort study

  27. Obesity (Silver Spring)

    The Sex‐Stratified Effects of RSPO3 Expression on Body Fat and Blood Lipids: An Omics Mendelian Randomization Study

    Research article

  28. Cardiovasc Diabetol

    Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study

    Cohort study

  29. Int J Obes (Lond)

    Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East

    Cohort study

  30. Cardiovasc Diabetol

    Association of the atherogenic index of plasma and its integrative novel adiposity-based composites with all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: novel adiposity-derived AIP indices provide modest incremental prognostic information

    Cohort study

  31. Int J Obes (Lond)

    Linking circulating chemerin and adiponectin to lipoprotein subclasses measured by 1H-NMR spectroscopy in 3199 participants from the study of health in Pomerania

    Cross-sectional study

  32. Diabetes Obes Metab

    Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

    Cohort study

  33. Cardiovasc Diabetol

    Associations of insulin resistance-related indices with the risk and progression of cardiometabolic multimorbidity in individuals with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

    Cohort study

  34. Cardiovasc Diabetol

    Burden trajectories of stroke attributable to lipid-glucose dysfunction and biomarker validation: evidence from the global burden of disease (GBD) 2023 and the China health and retirement longitudinal study (CHARLS)

    Secondary analysis

  35. Cardiovasc Diabetol

    Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study

    Cohort study

  36. Endocr Pract

    Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study

    Cohort study

  37. J Clin Endocrinol Metab

    Alcohol and steatotic liver disease exhibit divergent associations with high plasma small dense LDL-C concentration

    Cross-sectional study

  38. BMJ Open Diabetes Res Care

    Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus

    Cross-sectional study

  39. Cardiovasc Diabetol

    Growth differentiation factor-15 and the incidence, bidirectional progression, and risk prediction of atherosclerotic cardiovascular disease and metabolic dysfunction-associated steatotic liver disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3

    Cohort study

  40. Nat Med

    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

    Randomized controlled trial

All 460 Briefs in ExploreShowing the 40 most recently published